“Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials”. 2024. SKIN The Journal of Cutaneous Medicine 8 (2): s366. https://doi.org/10.25251/skin.8.supp.366.